Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?
TheFly reported on June 25 that Guggenheim raised its price target on AMLX to $40 from $30 while reaffirming its Buy rating.
Amylyx Pharmaceuticals Inc. (AMLX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 8,284,882 | $115,159,860 | 2.25% | |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 5,650,000 | $78,535,000 | 4.54% | |
| 3. | Saturn V Capital Management Xiaoying Tian | 4,349,885 | $60,463,402 | -4% | 10.95% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 3,560,764 | $49,494,620 | +29% | 0.08% |
| 5. | Driehaus Capital Richard Driehaus | 2,987,147 | $41,521,343 | -4% | 0.31% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.51 | 3,800 | $51,338.00 | 66,900 | 2026-05-21 | Filing | |
| $12.45 | 8,100 | $100,845.00 | 63,100 | 2025-12-23 | Filing | |
| $3.70 | 10,000 | $37,005.00 | 10,000 | 2025-03-20 | Filing | |
| $2.53 | 40,000 | $101,368.00 | 233,464 | 2024-09-12 | Filing | |
| $2.13 | 50,000 | $106,590.00 | 55,000 | 2024-09-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.47 | 29,282 | $423,760.32 | 3,334,616 | 2026-03-02 | Filing | |
| $14.48 | 29,282 | $424,120.49 | 3,334,683 | 2026-03-02 | Filing | |
| $14.58 | 6,461 | $94,205.26 | 169,295 | 2026-03-02 | Filing | |
| $14.52 | 7,909 | $114,851.33 | 165,638 | 2026-03-02 | Filing | |
| $14.52 | 6,844 | $99,378.30 | 134,430 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,838 | $194,650 | 0.1% | |
| 2. | 10,045 | $180,408 | 0% | |
| 3. | 721 | $12,949 | 0% | |
| 4. | 433 | $7,777 | 0% | |
| 5. | 420 | $7,543 | 0% |
News See All
12 Best Low-Priced Pharma Stocks to Buy Right Now
Investors looking for large returns without making a sizable initial commitment are still drawn to low-priced companies.
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress
TheFly reported on May 7 that AMLX reported first-quarter 2026 results for the period ended March 31, 2026, alongside pipeline and clinical updates.
8 Best Small Cap Pharma Stocks to Buy Right Now
Despite the concerns surrounding the Iran War, Haig Bathgate, CEO of Callanish Capital, stated on CNBC on May 7 that he was optimistic about global stocks.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2026 Earnings Call Transcript May 7, 2026Amylyx Pharmaceuticals, Inc. misses on earnings expectations.
7 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds
In this article, we will take a look at some of the small-cap drug manufacturing stocks that are highly favored by hedge funds.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript
Operator: Good morning, everyone. My name is Jim and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals, Inc.
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the overlooked growth stocks to buy.
9 Overlooked Growth Stocks to Buy
On January 12, Victoria Greene, Founding Partner and CIO at G Squared Private Wealth, joined CNBC to discuss her current market outlook, selecting 'Fundamentals' as her word of the day.
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc.
Hedge Fund Resource Center